Disruption of Human Papillomavirus 16 E6/E7 Genes Using All-in-One Adenovirus Vectors Expressing Eight Double-Nicking

Megumi Yamaji1, Tomomi Nakahara2, Tomoko Nakanishi1

  • 1Center of Biomedical Research Resources, Juntendo University School of Medicine, Tokyo 113-8421, Japan.

Insights

This study used a double-nicking CRISPR/Cas9 technique to target human papillomavirus (HPV) oncogenes, significantly reducing off-target effects for safer cancer therapy.

Area of Science:

  • Genomic Medicine
  • Oncology
  • Viral Oncology

Background:

  • Human papillomavirus (HPV) oncoproteins E6 and E7 are critical for cervical cancer development.
  • CRISPR/Cas9 genome editing offers a potential therapeutic strategy against HPV-induced cancers.
  • Minimizing off-target effects is essential for the clinical safety of CRISPR/Cas9 therapies.

Purpose of the Study:

  • To develop a precise genome-editing strategy targeting HPV16 E6 and E7 oncogenes.
  • To assess the efficacy and specificity of a double-nicking CRISPR/Cas9 approach.
  • To evaluate the therapeutic potential of an adenovirus-delivered system for HPV-positive cancers.

Main Methods:

  • Designed and selected double-nicking (DN)-gRNA pairs targeting HPV16 E6/E7 oncogenes.
  • Delivered DN-gRNA pairs and Cas9 nickase (Cas9n) to HPV16-positive cells using lentiviral vectors.
  • Utilized an all-in-one adenovirus (AdV) system for in vivo delivery of gRNAs and Cas9n.
  • Quantified cell killing, off-target effects, and tumor growth inhibition in preclinical models.

Main Results:

  • Multiple DN-gRNA pair combinations effectively eliminated HPV16-positive cancer cells while sparing normal cells.
  • Off-target mutations were reduced by nearly three orders of magnitude compared to standard CRISPR/Cas9.
  • The AdV-based system demonstrated significant inhibition of tumor growth in HPV16-positive cancer models.
  • The approach showed high specificity for HPV-infected cells.

Conclusions:

  • The double-nicking CRISPR/Cas9 technique offers enhanced safety and specificity for targeting HPV oncogenes.
  • Adenovirus-mediated delivery of this system presents a promising therapeutic strategy for HPV-induced malignancies.
  • This genome-editing approach holds potential for developing safer and more effective treatments for HPV-related cancers.

Related Concept Videos

Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...